2,397 results on '"Wallace, Daniel"'
Search Results
352. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
353. Raynaud’s Phenomenon From PD-1 Immune Checkpoint Inhibition
354. Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-Induced Lupus Model
355. Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort
356. Dysregulated hepcidin response to dietary iron in male mice with reduced Gnpat expression
357. American Indians Have a Higher Risk of Sjögren's Syndrome and More Disease Activity Than European Americans and African Americans
358. Five‐Year Follow‐Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Community‐Based Lupus Cohort
359. Evidence for dimerization of ferroportin in a human hepatic cell line using proximity ligation assays
360. ATP7B variant penetrance explains differences between genetic and clinical prevalence estimates for Wilson disease
361. Cell-bound complement activation products associate with lupus severity in SLE
362. Design and evaluation of personal audio systems based on speech privacy constraints
363. O4 Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus
364. O8 Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease
365. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study
366. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index
367. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach
368. The Daily Discoveries of a Bible Scholar and Manuscript Hunter: A Biography of James Rendel Harris (1852–1941) by Alessandro Falcetta
369. Remembering Randall: Written Roundtable
370. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus
371. Robot-Assisted Antegrade In-Situ Fenestrated Stent Grafting
372. Preface
373. Acknowledgments
374. Thrombovascular events in systemic lupus erythematosus: Comment on the article by Jung et al
375. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study
376. Telomere Diseases
377. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
378. Human Systems Engineering Process and Methods
379. Prohepcidin localises to the Golgi compartment and secretory pathway in hepatocytes
380. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
381. Novel Evidence-Based Systemic Lupus Erythematosus Responder Index
382. Dysfunctional Proinflammatory High-Density Lipoproteins Confer Increased Risk of Atherosclerosis in Women With Systemic Lupus Erythematosus
383. Chronic Inflammatory Demyelinating Polyneuropathy in Patients with Systemic Lupus Erythematosus: Prognosis and Outcome
384. New Insights Into Systemic Lupus Erythematosus Therapies: 2010–2020.
385. Juvenile iron overload—Advances, but no answers
386. Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?
387. Celecoxib for lupus
388. Abetimus Sodium for Renal Flare in Systemic Lupus Erythematosus: Results of a Randomized, Controlled Phase III Trial
389. Additional components to measuring fatigue in patients with systemic lupus erythematosus: comment on the article by the Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue
390. Systemic Lupus International Collaborating Clinics Renal Activity/Response Exercise: Development of a Renal Activity Score and Renal Response Index
391. Systemic Lupus International Collaborating Clinics Renal Activity/Response Exercise: Comparison of Agreement in Rating Renal Response
392. Osteopontin versus disease activity and damage accrual in recent-onset systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort
393. How to Help Yourself without Taking Medicine
394. Who Gets Fibromyalgia and Why?
395. The Fibromyalgia Consultation and Differential Diagnosis
396. Medicines for Fibromyalgia
397. I’m Not Crazy!
398. What Is Fibromyalgia?
399. Prognosis and Future Directions
400. Fibromyalgia-Related Complaints
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.